Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) is a global healthcare solutions provider focused on medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. This news page aggregates company announcements, press releases, and other updates related to GE HealthCare’s business activities and capital markets disclosures.
Visitors can find news about GE HealthCare’s collaborations with health systems, governments, and academic institutions, such as agreements to supply advanced CT scanners under national programs, multi-year care alliances with medical centers, and research initiatives in radiation therapy and oncology. The company also issues news on product and technology developments, including imaging systems, AI-powered reconstruction tools, radiology workflow software, and other innovations that it associates with advancing precision care.
GE HealthCare’s news flow includes corporate and investor-focused items as well. Examples include announcements of upcoming earnings releases, participation in healthcare and investor conferences, and responses to shareholder-related matters such as unsolicited mini-tender offers. These communications provide context on how the company presents its strategy, financing activities, and interactions with the capital markets.
Because GE HealthCare emphasizes integrated solutions across Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, many news items highlight how these businesses work together in specific projects or collaborations. Readers can expect coverage of topics such as AI-enabled imaging, diagnostic access initiatives, training and innovation hubs, and alliances aimed at supporting more efficient and precise care. Investors and observers who follow GEHC news can use this page as a centralized view of the company’s publicly released information and developments over time.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) has announced a secondary public offering of 10,000,000 shares of its common stock. The company itself is not selling any shares or receiving proceeds from the sale. Prior to the offering's closing, GE Aerospace is expected to exchange the GEHC shares for debt held by Morgan Stanley affiliates. The selling stockholder has granted underwriters an option to purchase an additional 1,500,000 shares for settlement by September 30, 2024. Morgan Stanley and Citigroup are acting as lead joint book-running managers for the offering. The company has filed an automatically effective shelf registration statement with the SEC for this offering.
GE HealthCare (Nasdaq: GEHC) announced CE marks for two innovative cardiology solutions: the Vscan Air™ SL with Caption AI™, an AI-driven handheld ultrasound system for rapid cardiac assessments, and ECG-less Cardiac CT scanning on its Revolution Apex™ platform. These technologies aim to enable more efficient and timely cardiac care at the point of service.
The Vscan Air SL with Caption AI provides real-time guidance for capturing cardiac images, even for non-experts, and includes an AutoEF feature for calculating left ventricular ejection fraction. The ECG-less Cardiac CT solution allows for cardiac imaging without an ECG signal, prioritizing patient access and speed.
Both innovations will be showcased at the European Society of Cardiology (ESC) Congress in London, August 30-September 2, 2024, along with GE HealthCare's Allia™ IGS 5 Pulse image-guided platform for interventional cardiology.
GE HealthCare (Nasdaq: GEHC) has announced its management's participation in two upcoming investor conferences in September 2024. The company will be presenting at the 2024 Wells Fargo Healthcare Conference in Boston on September 4 at 10:15 am ET, and the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5 at 1:05 pm ET.
Investors and interested parties can access these presentations through the GE HealthCare Investor Relations website. This announcement highlights the company's commitment to engaging with investors and sharing insights about its operations and future prospects in the healthcare industry.
GE HealthCare (Nasdaq: GEHC) announced the publication of the MASTER trial results in Anesthesia and Analgesia, demonstrating the safety and efficacy of End-tidal Control software for inhaled anesthetic administration. The study, conducted across four U.S. hospitals with 210 adult patients, showed that End-tidal Control achieved:
- Targeted end-tidal anesthetic concentrations within 5% of the set value 98% of the time, compared to 46% with manual control
- Targeted end-tidal oxygen concentrations within 5% of the set value 86% of the time, versus 41% with manual control
- Faster response times for achieving 90% of the initial desired end-tidal anesthetic concentration (median 75 seconds vs. 158 seconds)
The software also demonstrated potential to reduce anesthetic agent usage, greenhouse gas emissions, and costs compared to manual control.
GE HealthCare has announced a collaboration with the University of California San Diego School of Medicine to develop advanced MRI protocols and educational materials for women's pelvic imaging. The project, led by Dr. Rebecca Rakow-Penner, aims to improve diagnosis and management of female pelvic diseases such as endometriosis and ovarian cancer. This initiative addresses the gap in medical research and care for women's pelvic health, which is often understudied and misdiagnosed.
The collaboration seeks to democratize advanced imaging for women and increase access to high-quality care. By creating training materials and protocols, the project aims to equip clinicians worldwide with tools to deliver better care. This could potentially improve patient experiences and help clinicians make more informed decisions, ultimately bridging an important gap in women's healthcare.
GE HealthCare (GEHC) reported its Q2 2024 financial results, with flat revenues at $4.8 billion year-over-year and 1% organic revenue growth. The net income margin increased slightly to 8.9% from 8.7%, and adjusted EBIT margin rose to 15.3% from 14.8%. Diluted EPS improved to $0.93 from $0.91, while adjusted EPS grew to $1.00 from $0.92. However, the company experienced a decline in cash flow from operating activities to $(119) million from $(67) million and free cash flow to $(182) million from $(136) million.
Segment performance varied, with Imaging revenue down 1%, Ultrasound down 2%, Patient Care Solutions flat, and Pharmaceutical Diagnostics up 12%. GE HealthCare revised its full-year guidance, lowering organic revenue growth to 1-2% from approximately 4%, but raising adjusted EBIT margin to 15.7-16.0% from 15.6-15.9%.
CEO Peter Arduini highlighted strong orders growth in the U.S. and ongoing investments in future growth despite challenges in the China market. The company also announced several strategic collaborations and acquisitions to advance healthcare technologies.
GE HealthCare (GEHC) and Amazon Web Services (AWS) have announced a strategic collaboration to develop generative AI applications for healthcare. GE HealthCare has selected AWS as its strategic cloud provider to build and implement new foundation models aimed at transforming healthcare. The collaboration will utilize AWS services like Amazon Bedrock, Amazon Q Developer, and Amazon SageMaker to accelerate the development of medical technologies and streamline clinical workflows.
The partnership aims to improve diagnostic accuracy, enhance patient outcomes, and promote equitable care. GE HealthCare plans to leverage AWS's healthcare-specific cloud services and generative AI capabilities to build transformative clinical foundation models and applications, potentially reducing application development cycles from years to months.
GE HealthCare (Nasdaq: GEHC) has announced an agreement to acquire Intelligent Ultrasound Group's clinical AI software business for approximately $51 million. This acquisition aims to enhance GE HealthCare's ultrasound portfolio with AI-driven image analysis tools, improving workflow efficiency and ease-of-use for clinicians.
Key highlights include:
- Integration of Intelligent Ultrasound's ScanNav Assist AI technology into GE HealthCare's ultrasound systems
- Addition of R&D experts to drive AI-enabled innovation in Women's Health ultrasound devices
- Support for GE HealthCare's precision care strategy to address inefficiencies and improve patient care quality
The transaction is expected to close in Q4 2024, subject to customary closing conditions.
GE HealthCare (Nasdaq: GEHC) will reveal its second quarter 2024 financial results on July 31, 2024, before the market opens.
The announcement will be followed by a conference call and webcast at 8:30 a.m. Eastern Time, accessible via the company's Investor Relations website.
The webcast, earnings release, and related financial documents will also be available for replay on the same platform.
GE HealthCare Technologies (Nasdaq: GEHC) has announced a cash dividend of $0.03 per share for the second quarter of 2024. This dividend will be payable on August 15, 2024, to shareholders who are on record as of July 19, 2024. The announcement reflects the company’s ongoing commitment to returning value to its shareholders.
FAQ
What is the current stock price of Ge Healthcare Technologies (GEHC)?
What is the market cap of Ge Healthcare Technologies (GEHC)?
